REBECCA Real-world Early BrEast CanCer mAnagement
Launched by ASTRAZENECA · Feb 26, 2025
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
The REBECCA trial is a study taking place in France that looks at how well a medication called olaparib works for patients with a specific type of breast cancer known as HER2-negative early breast cancer (eBC). This study is observational, meaning the researchers will be watching how patients respond to the treatment rather than assigning them to different treatment groups. The trial is currently recruiting participants who are 18 years or older and are planning to start olaparib treatment based on their doctor's advice.
To be eligible for the study, patients must be diagnosed with HER2-negative eBC and must agree to participate after being informed about the study. If someone is not comfortable with the idea of being part of the trial or is already part of another program for early access to treatments, they won't be able to join. Participants in this study can expect regular check-ins to monitor their health and response to the treatment, helping researchers gather important information about how olaparib works in real-world settings.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female aged ≥ 18 years
- • Patient diagnosed with HER2-negative eBC
- • Patient about to be initiated with adjuvant Olaparib at their physician's discretion
- • Patient has been informed and does not object to participation in the study.
- Exclusion Criteria:
- • Patient not consenting to participate.
- • Patients included in the Early Access Program
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montpellier, , France
Montpellier Cedex 5, , France
Lille Cedex, , France
Caen, , France
Grenoble, , France
Perigueux, , France
Chambray Les Tours, , France
Dechy, , France
Salouel, , France
Paris Cedex 14, , France
Creil Cedex 1, , France
Nancy, , France
Beuvry, , France
Poitiers Cedex, , France
Lyon Cedex 04, , France
Gleize, , France
Limoges Cedex 1, , France
St Brieuc Cedex 1, , France
Thonon Les Bains, , France
Valence, , France
Avignon Cedex 9, , France
Compiegne Cedex, , France
Le Blanc Mesnil, , France
Osny, , France
St Doulchard, , France
St Martin Boulogne, , France
Champigny Sur Marne Cedex, , France
Marseille Cedex 05, , France
St Priest En Jarez Cedex, , France
Fort De France Cedex, , France
Nice Cedex 2, , France
Rouen Cedex, , France
Beauvais Cedex, , France
Metz Tessy, , France
Valence Cedex 9, , France
Frejus Cedex, , France
Argenteuil Cedex, , France
St Gregoire Cedex, , France
St Pierre Cedex, , France
Agen Cedex 9, , France
Bezannes, , France
Clermont Ferrand Cedex 2, , France
Plerin Cedex, , France
St Etienne Cedex 2, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported